SMUG1 regulates fat homeostasis leading to a fatty liver phenotype in mice

Carracedo, Sergio; Lirussi, Lisa; Alsøe, Lene; Segers, Filip M.; Wang, Changliang; Bartošová, Zdeňka; Bohov, Pavol; Tekin, Nuriye Basdag; Kong, Xiang Yi; Esbensen, Qin Ying; Chen, Liang; Wennerström, Anna; Kroustallaki, Penelope; Ceolotto, Deborah; Tönjes, Anke; Berge, Rolf K.; Bruheim, Per; Wong, Garry; Böttcher, Yvonne; Halvorsen, Bente; Nilsen, Hilde

doi:10.1016/j.dnarep.2022.103410

Cited by 1 publication

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Starting with monofunctional glycosylases, UNG KO was the first example of cancer development without a carcinogen and increased incidence of B-cell lymphomas in old age [ 80 ]. SMUG1 was shown to be an essential glycosylase to modulate fat metabolism [ 81 ]. SMUG1 KO in one-year-old mice increased weight and fat content and changed activity in enzymes needed for fatty acid regulation.…”

Section: Biology and Physiologymentioning

confidence: 99%

Base Excision Repair: Mechanisms and Impact in Biology, Disease, and Medicine

Gohil,

Sarker,

Roy

2023

IJMS

View full text Add to dashboard Cite

Base excision repair (BER) corrects forms of oxidative, deamination, alkylation, and abasic single-base damage that appear to have minimal effects on the helix. Since its discovery in 1974, the field has grown in several facets: mechanisms, biology and physiology, understanding deficiencies and human disease, and using BER genes as potential inhibitory targets to develop therapeutics. Within its segregation of short nucleotide (SN-) and long patch (LP-), there are currently six known global mechanisms, with emerging work in transcription- and replication-associated BER. Knockouts (KOs) of BER genes in mouse models showed that single glycosylase knockout had minimal phenotypic impact, but the effects were clearly seen in double knockouts. However, KOs of downstream enzymes showed critical impact on the health and survival of mice. BER gene deficiency contributes to cancer, inflammation, aging, and neurodegenerative disorders. Medicinal targets are being developed for single or combinatorial therapies, but only PARP and APE1 have yet to reach the clinical stage.

show abstract

Section: Biology and Physiologymentioning

confidence: 99%